Protease-Activated Receptors (PARs) are Partly Pro-Inflammatory and Partly Anti-Inflammatory: Will PAR Agonists or Antagonists Participate in Future Drug Therapies?

Author(s): B. A. De Campo, P. J. Henry

Journal Name: Current Drug Targets

Volume 7 , Issue 5 , 2006

Become EABM
Become Reviewer


Protease-activated receptors (PARs) are characterised by a unique mechanism of activation, which enables them to act as cellular sensors for protease activity. PARs are expressed throughout the cardiovascular, gastrointestinal and pulmonary systems, where they are potential drug targets for the treatment of disease. However, there are currently very few selective PAR antagonists or potent PAR agonists available as effective research tools, and moreover, there is considerable evidence to suggest that PARs can promote both pro-inflammatory and anti-inflammatory responses in a wide range of disease models. These confounding issues have, to date, prevented us from developing a clear understanding of the role of PARs in disease. Nevertheless, this review provides an overview of the distribution and function of PARs in the cardiovascular, gastrointestinal and pulmonary systems, and attempts to evaluate whether PAR agonists or antagonists have a place in future drug therapy.

Keywords: Protease-activated receptor, respiratory system, airway, gastrointestinal tract, cardiovascular system, asthma, thrombin, trypsin, protease, coagulation

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [629 - 637]
Pages: 9
DOI: 10.2174/138945006776818656
Price: $65

Article Metrics

PDF: 2